KRAS and lung adenocarcinoma: A case report of three patients with lung adenocarcinoma who developed pseudoprogression after anti‐PD‐1 therapy showed similar results in that when compared with the increase in patients with true progression, the level of KRAS‐mutated ctDNA was dramatically reduced to an undetectable level.175